[go: up one dir, main page]

ZA200605555B - Compositions and methods of administering tubulin binding agents for the treatment of ocular disease - Google Patents

Compositions and methods of administering tubulin binding agents for the treatment of ocular disease

Info

Publication number
ZA200605555B
ZA200605555B ZA200605555A ZA200605555A ZA200605555B ZA 200605555 B ZA200605555 B ZA 200605555B ZA 200605555 A ZA200605555 A ZA 200605555A ZA 200605555 A ZA200605555 A ZA 200605555A ZA 200605555 B ZA200605555 B ZA 200605555B
Authority
ZA
South Africa
Prior art keywords
compositions
treatment
methods
binding agents
ocular disease
Prior art date
Application number
ZA200605555A
Other languages
English (en)
Inventor
Sherris David
Wood Mark
Original Assignee
Oxigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene Inc filed Critical Oxigene Inc
Publication of ZA200605555B publication Critical patent/ZA200605555B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA200605555A 2003-12-09 2006-07-05 Compositions and methods of administering tubulin binding agents for the treatment of ocular disease ZA200605555B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/732,680 US20040229960A1 (en) 2001-07-13 2003-12-09 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
ZA200605555B true ZA200605555B (en) 2007-12-27

Family

ID=34677177

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200605555A ZA200605555B (en) 2003-12-09 2006-07-05 Compositions and methods of administering tubulin binding agents for the treatment of ocular disease

Country Status (12)

Country Link
US (1) US20040229960A1 (zh)
EP (1) EP1696933A4 (zh)
JP (1) JP2007513954A (zh)
KR (1) KR20060121281A (zh)
CN (1) CN1901919A (zh)
AU (1) AU2004296805A1 (zh)
CA (1) CA2548427A1 (zh)
IL (1) IL176227A0 (zh)
MX (1) MXPA06006606A (zh)
RU (1) RU2359693C2 (zh)
WO (1) WO2005056018A1 (zh)
ZA (1) ZA200605555B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092774A1 (en) * 2001-10-17 2003-05-15 Parkinson Thomas M. Methods for treating neoplastic, angiogenic, vascular, fibroblastic, and/or immunosuppressive iregularities of the eye and/or joint via administration of combretastatin based medicaments, and iontophoretic devices for delivering combretastatin based medicaments
WO2006138608A2 (en) * 2005-06-16 2006-12-28 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
US20100068141A1 (en) * 2005-07-27 2010-03-18 University Of Florida Use of heat shock to treat ocular disease
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
CA2720982A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
EP2144888A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHODS OF TREATING CANCER
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
AU2010266109A1 (en) * 2009-07-02 2012-02-02 Oxigene, Inc. Combretastatins for prevention of posterior capsule opacification
US20120157521A1 (en) * 2009-08-27 2012-06-21 Bonomics Limited Treatment of macular degeneration
CA2790407A1 (en) * 2010-03-11 2011-09-15 Oxigene, Inc. Ophthalmic formulations
CN110506634B (zh) * 2019-09-29 2022-07-05 上海市农业科学院 一种鸢尾化学诱变剂量筛选方法
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JP2001518935A (ja) * 1997-03-26 2001-10-16 バイオソース テクノロジーズ，インコーポレイティド 抗癌剤としてのジ―アリールエーテル類及びそれらの誘導体
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6271220B1 (en) * 1998-03-11 2001-08-07 Allergan Sales, Inc. Anti-angiogenic agents
AU3109199A (en) * 1998-03-25 1999-10-18 Large Scale Biology Corporation Benzoates derivatives for inhibiting angiogenesis
US6201001B1 (en) * 1999-08-02 2001-03-13 Abbott Laboratories Imidazole antiproliferative agents
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
CA2453442C (en) * 2001-07-13 2011-02-01 Oxigene, Inc. Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Also Published As

Publication number Publication date
RU2006124557A (ru) 2008-01-20
AU2004296805A1 (en) 2005-06-23
RU2359693C2 (ru) 2009-06-27
MXPA06006606A (es) 2006-08-31
EP1696933A4 (en) 2007-06-20
JP2007513954A (ja) 2007-05-31
IL176227A0 (en) 2006-10-05
KR20060121281A (ko) 2006-11-28
WO2005056018A1 (en) 2005-06-23
CA2548427A1 (en) 2005-06-23
EP1696933A1 (en) 2006-09-06
US20040229960A1 (en) 2004-11-18
CN1901919A (zh) 2007-01-24

Similar Documents

Publication Publication Date Title
ZA200605555B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular disease
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
IL174627A0 (en) Compositions and methods for treatment of burns
EP1737453A4 (en) METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
EP1575480A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
EP1578367A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1572116A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1576137A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
EP1571968A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
EP1589933A4 (en) COMPOSITIONS AND METHODS FOR DIETUMOR DIAGNOSIS AND TREATMENT
EP1572091A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
EP1578996A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EP1553912A4 (en) COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
HK1162127A1 (zh) 用於減少心血管疾病風險的油體締合蛋白質的組合物和方法及其用途
EP1575571A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
AU2003286741A8 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1542664A4 (en) METHODS AND COMPOSITIONS FOR TREATING MACULAR AND RETINAL DISORDERS
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
EP1753445A4 (en) TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases